IMPORTANT MESSAGE
Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Agility and expertise combine to overcome late stage design issues in comparator study
There are multiple points of a clinical trial’s route-map where the success of the study can be derailed. When it comes to sourcing comparator products to effectively assess an Investigational Product’s (IP) performance against the current standard of care, there’s a lot that can go wrong.
For instance, the current global supply shortages in particular therapeutic areas can driveup procurement costs and supply complexity, by forcing sponsors to source product from multiple suppliers and regions. Likewise, if comparator drugs are unexpectedly discontinued, sponsors may be faced with leaving patients in limbo while they update and resubmit the Clinical Trial Authorisation (CTA) to relevant regulatory bodies.
Download the case study to find out more.